The therapeutic potential of novel anti-migraine acute therapies

Expert Opinion on Investigational Drugs

Volumn 24, Issue 2, 2015, Pages 141-144

  Sabato, Donata ^a   Lionetto, Luana ^b   Martelletti, Paolo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Migraine; New therapies; Pathophysiological targets; Receptor agonists; Receptor antagonists; Receptors

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; BI 44370; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR; LASMIDITAN; MAXADILAN; METABOTROPIC RECEPTOR; MK 3207; NXN 188; OLCEGEPANT; PLACEBO; RIMEGEPANT; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TELCAGEPANT; TEZAMPANEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; HUMAN; MIGRAINE; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MIGRAINE DISORDERS; MOLECULARLY TARGETED THERAPY;

ANIMALS; DRUG DESIGN; HUMANS; MIGRAINE DISORDERS; MOLECULAR TARGETED THERAPY; RECEPTORS, GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84921278364     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.983223     Document Type: Review

References (22)

1. Martelletti P, Birbeck GL, Katsarava Z, et al. The global burden of disease survey. 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain 2013;14:13
2. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12:570-84
3. Lionetto L, Casolla B, Mastropietri F, et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol 2012;8:1043-50
4. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004;56:371-81
5. Shields KG, Goadsby PJ. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 2006;23:491-501
6. Tso AR, Goadsby PJ. New targets for migraine therapy. Curr Treat Options Neurol 2014;16:318
7. Bell IM. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. J Med Chem 2014;57(19):7838-7858
8. Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21:807-18
9. Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 2013;93:78-85
10. Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008;28:226-36
11. Edvinsson L. PACAP and its receptors in migraine pathophysiology. Br J Pharmacol 2014; [Epub ahead of print]
12. Banki E, Hajna Z, Kemeny A, et al. The selective PAC1 receptor agonist maxadilan inhibits neurogenic vasodilation and edema formation in the mouse skin. Neuropharmacology 2014;85:538-47
13. Rainero I, Rubino E, Paemeleire K, et al. Genes and primary headaches: discovering new potential therapeutic targets. J Headache Pain 2013;14:61
14. Costa C, Tozzi A, Rainero I, et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain 2013;14:62
15. Holland PR, Akerman S, Goadsby PJ. Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors. Cephalalgia 2010;30:519-27
16. Andreou AP1, Holland PR, Goadsby PJ. Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol 2009;157:464-73
17. Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17:393-406
18. Benemei S, Fusi C, Trevisan G, et al. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol 2014;171:2552-67
19. Benemei S, De Cesaris F, Fusi C, et al. TRPA1 and other TRP channels in migraine. J Headache Pain 2013;14:71 doi: 10.1186/1129-2377-14-71
20. Farinelli I, De Filippis S, Coloprisco G, et al. Future drugs for migraine. Intern Emerg Med 2009;4:367-73
21. Cevoli S, D'Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 2009;29:1285-93
22. Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 2012;13:361-78